Compare Dow Inc (DOW) vs Viatris Inc (VTRS) Price & Performance

DOW trades at $27.77, down 1.38% with bearish technical signals. The company faces fundamental challenges with negative net income margin (-3.13%) and ROE (-7.86%) despite beating recent EPS estimates. Revenue declined from $56.9B in 2022 to $40.0B in 2025, though 2026 projections show modest recovery to $41.3B. Analyst consensus is mixed with 28% buy ratings but a $34.22 price target suggesting 23% upside potential from current levels.

DOW presents a high-risk opportunity with significant valuation disconnect. While technicals are bearish and profitability metrics weak, the stock trades at attractive valuation multiples (P/S: 0.5x, P/B: 1.3x) with dividend support. Key risks include ongoing margin pressure, declining operating cash flow trend, and rising debt-to-asset ratio approaching 30%. The investment case hinges on earnings recovery and operational turnaround execution.

Viatris (VTRS) trades at $17.49, down 0.29% with a bullish technical signal supported by moving averages and oversold RSI levels. The company shows consistent earnings beats with Q2 2026 EPS of $0.69 exceeding expectations, while maintaining strong operational cash flow of $2.32B in 2025. Recent developments include FDA approval for WAKIX in Japan and continued recognition as a top employer.

Despite negative net margins, Viatris demonstrates improving cash flow trends and strategic portfolio optimization. The stock offers 27% upside to consensus price target of $22.17, though investors face risks from debt levels and competitive pressures in the generic drug market. Deleveraging progress and pipeline advancements support potential re-rating.